H3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. [electronic resource]
- Laboratory investigation; a journal of technical methods and pathology May 2007
- 473-87 p. digital
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
0023-6837
10.1038/labinvest.3700533 doi
Animals Bile Ducts--surgery Bile Ducts, Intrahepatic--drug effects Cell Proliferation--drug effects Cyclic AMP--metabolism Cyclic AMP-Dependent Protein Kinases Disease Models, Animal Down-Regulation--drug effects Drug Therapy, Combination Gene Expression Regulation, Enzymologic--drug effects Histamine--pharmacology Histamine Agonists--pharmacology Hyperplasia--chemically induced Ligation Liver--drug effects MAP Kinase Signaling System Male Methylhistamines--pharmacology Mitogen-Activated Protein Kinase 1--metabolism Mitogen-Activated Protein Kinase 3--metabolism Mitogen-Activated Protein Kinases--metabolism Phosphorylation Piperidines--pharmacology Protein Serine-Threonine Kinases--metabolism Rats Rats, Inbred F344 Receptor, EphA8--metabolism Receptors, Histamine H3--genetics